Rebuilding momentum in life sciences: Capital markets, innovation and the path forward

The life sciences sector entered 2026 with renewed momentum following a period of market volatility, constrained capital and macroeconomic uncertainty. At the 2026 J.P. Morgan Healthcare Conference and Market Update Dinner, industry leaders from Baker Tilly, J.P. Morgan and the Allen Institute discussed the current biotech market, investment trends and emerging scientific innovations shaping the future of the industry.

The conversation highlighted a cautiously optimistic outlook. Capital markets are reopening selectively, strategic acquisitions are gaining momentum and new translational research initiatives are helping bring breakthrough science closer to commercialization. At the same time, macroeconomic conditions, policy volatility and global competition continue to influence investor sentiment and industry strategy.

While challenges remain, strong scientific innovation combined with improving capital market conditions is positioning the industry for the next phase of growth.

A strengthening biotech market environment

A key theme from the discussion was the improving outlook for biotechnology markets after several challenging years for investors and emerging companies alike. Insights shared from the J.P. Morgan Healthcare Conference indicate that biotech experienced a notable rebound in 2025. For the first time since the COVID-era market surge in 2020, biotech outperformed broader market benchmarks, signaling renewed investor confidence in innovation-driven healthcare companies.

That recovery did not occur evenly. In the first half of 2025, investor skepticism remained high, with even companies reporting positive clinical results facing declining share prices. Expectations had shifted and investors increasingly required clear differentiation, strong clinical outcomes and well-defined development strategies.

Conditions improved in the second half of the year. Investors began rewarding strong clinical catalysts, clinical-stage biotech companies outperformed larger commercial peers and capital formation accelerated through follow-on offerings. These shifts suggest a renewed appetite for risk in biotechnology, particularly when supported by compelling science and credible development strategies.